GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » PB Ratio

PBYI (Puma Biotechnology) PB Ratio : 1.70 (As of Jun. 30, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-06-30), Puma Biotechnology's share price is $3.33. Puma Biotechnology's Book Value per Share for the quarter that ended in Mar. 2025 was $1.96. Hence, Puma Biotechnology's PB Ratio of today is 1.70.

The historical rank and industry rank for Puma Biotechnology's PB Ratio or its related term are showing as below:

PBYI' s PB Ratio Range Over the Past 10 Years
Min: 1.44   Med: 12.53   Max: 69.99
Current: 1.7

During the past 13 years, Puma Biotechnology's highest PB Ratio was 69.99. The lowest was 1.44. And the median was 12.53.

PBYI's PB Ratio is ranked better than
64.66% of 1282 companies
in the Biotechnology industry
Industry Median: 2.505 vs PBYI: 1.70

During the past 12 months, Puma Biotechnology's average Book Value Per Share Growth Rate was 85.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Puma Biotechnology was 25.30% per year. The lowest was -57.30% per year. And the median was 1.50% per year.

Back to Basics: PB Ratio


Puma Biotechnology PB Ratio Historical Data

The historical data trend for Puma Biotechnology's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology PB Ratio Chart

Puma Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 9.08 3.86 1.63

Puma Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.01 3.26 1.76 1.63 1.51

Competitive Comparison of Puma Biotechnology's PB Ratio

For the Biotechnology subindustry, Puma Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's PB Ratio distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's PB Ratio falls into.


;
;

Puma Biotechnology PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Puma Biotechnology's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2025)
=3.33/1.957
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Puma Biotechnology  (NAS:PBYI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Puma Biotechnology PB Ratio Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Puma Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Executives
Maximo F Nougues officer: Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig officer: Chief Commercial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt officer: See Remarks C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Alan H Auerbach director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Michael Patrick Miller director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes director
Adrian Senderowicz director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Troy Edward Wilson director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Alvin F Wong officer: Chief Scientific Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce officer: SR VP, CLINICAL RESEARCH & DEV C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd director C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139